176 related articles for article (PubMed ID: 24330823)
1. The therapeutic efficacy of I131-PSCA-mAb in orthotopic mouse models of prostate cancer.
Yu S; Feng F; Wang K; Men C; Lin C; Liu Q; Yang D; Gao Z
Eur J Med Res; 2013 Dec; 18(1):56. PubMed ID: 24330823
[TBL] [Abstract][Full Text] [Related]
2. MRl of prostate cancer antigen expression for diagnosis and immunotherapy.
Ren J; Wang F; Wei G; Yang Y; Liu Y; Wei M; Huan Y; Larson AC; Zhang Z
PLoS One; 2012; 7(6):e38350. PubMed ID: 22761679
[TBL] [Abstract][Full Text] [Related]
3. Dual-Modality Immuno-PET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer Using an Anti-Prostate Stem Cell Antigen Cys-Diabody.
Zettlitz KA; Tsai WK; Knowles SM; Kobayashi N; Donahue TR; Reiter RE; Wu AM
J Nucl Med; 2018 Sep; 59(9):1398-1405. PubMed ID: 29602820
[TBL] [Abstract][Full Text] [Related]
4. Prostate stem cell antigen antibody-conjugated multiwalled carbon nanotubes for targeted ultrasound imaging and drug delivery.
Wu H; Shi H; Zhang H; Wang X; Yang Y; Yu C; Hao C; Du J; Hu H; Yang S
Biomaterials; 2014 Jul; 35(20):5369-5380. PubMed ID: 24709520
[TBL] [Abstract][Full Text] [Related]
5. Applications of immunoPET: using 124I-anti-PSCA A11 minibody for imaging disease progression and response to therapy in mouse xenograft models of prostate cancer.
Knowles SM; Tavaré R; Zettlitz KA; Rochefort MM; Salazar FB; Jiang ZK; Reiter RE; Wu AM
Clin Cancer Res; 2014 Dec; 20(24):6367-78. PubMed ID: 25326233
[TBL] [Abstract][Full Text] [Related]
6. [
Zettlitz KA; Tsai WK; Knowles SM; Salazar FB; Kobayashi N; Reiter RE; Wu AM
Mol Imaging Biol; 2020 Apr; 22(2):367-376. PubMed ID: 31209779
[TBL] [Abstract][Full Text] [Related]
7. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
8. MRI of prostate stem cell antigen expression in prostate tumors.
Ren J; Zhang Z; Wang F; Yang Y; Liu Y; Wei G; Yang A; Zhang R; Huan Y; Cui Y; Larson AC
Nanomedicine (Lond); 2012 May; 7(5):691-703. PubMed ID: 22630152
[TBL] [Abstract][Full Text] [Related]
9. RNA interference targeting PSCA suppresses primary tumor growth and metastasis formation of human prostate cancer xenografts in SCID mice.
Zhao Z; He J; Kang R; Zhao S; Liu L; Li F
Prostate; 2016 Feb; 76(2):184-98. PubMed ID: 26477693
[TBL] [Abstract][Full Text] [Related]
10. The Anti-Proliferative Effect of a Newly-Produced Anti-PSCA-Peptide Antibody by Multiple Bioinformatics Tools, on Prostate Cancer Cells.
Chizari M; Fani-Kheshti S; Taeb J; Farajollahi MM; Mohsenzadegan M
Recent Pat Anticancer Drug Discov; 2021; 16(1):73-83. PubMed ID: 33176663
[TBL] [Abstract][Full Text] [Related]
11. Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumors.
Leyton JV; Olafsen T; Lepin EJ; Hahm S; Bauer KB; Reiter RE; Wu AM
Clin Cancer Res; 2008 Nov; 14(22):7488-96. PubMed ID: 19010866
[TBL] [Abstract][Full Text] [Related]
12. Redirection of CD4+ and CD8+ T lymphocytes via a novel antibody-based modular targeting system triggers efficient killing of PSCA+ prostate tumor cells.
Arndt C; Feldmann A; Töpfer K; Koristka S; Cartellieri M; Temme A; Ehninger A; Ehninger G; Bachmann M
Prostate; 2014 Sep; 74(13):1347-58. PubMed ID: 25053504
[TBL] [Abstract][Full Text] [Related]
13. Dual-Modality ImmunoPET/Fluorescence Imaging of Prostate Cancer with an Anti-PSCA Cys-Minibody.
Tsai WK; Zettlitz KA; Tavaré R; Kobayashi N; Reiter RE; Wu AM
Theranostics; 2018; 8(21):5903-5914. PubMed ID: 30613270
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of [
Tsai WK; Zettlitz KA; Dahlbom M; Reiter RE; Wu AM
Mol Imaging Biol; 2020 Oct; 22(5):1380-1391. PubMed ID: 32661830
[TBL] [Abstract][Full Text] [Related]
15. Small interference RNA-mediated silencing of prostate stem cell antigen attenuates growth, reduces migration and invasion of human prostate cancer PC-3M cells.
Zhao Z; Ma W; Zeng G; Qi D; Ou L; Liang Y
Urol Oncol; 2013 Apr; 31(3):343-51. PubMed ID: 21429770
[TBL] [Abstract][Full Text] [Related]
16. Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice.
Hillerdal V; Ramachandran M; Leja J; Essand M
BMC Cancer; 2014 Jan; 14():30. PubMed ID: 24438073
[TBL] [Abstract][Full Text] [Related]
17. Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts.
Saffran DC; Raitano AB; Hubert RS; Witte ON; Reiter RE; Jakobovits A
Proc Natl Acad Sci U S A; 2001 Feb; 98(5):2658-63. PubMed ID: 11226295
[TBL] [Abstract][Full Text] [Related]
18. An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors.
Lepin EJ; Leyton JV; Zhou Y; Olafsen T; Salazar FB; McCabe KE; Hahm S; Marks JD; Reiter RE; Wu AM
Eur J Nucl Med Mol Imaging; 2010 Aug; 37(8):1529-38. PubMed ID: 20354850
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cell-directed vaccination with a lentivector encoding PSCA for prostate cancer in mice.
Xiao L; Joo KI; Lim M; Wang P
PLoS One; 2012; 7(11):e48866. PubMed ID: 23139820
[TBL] [Abstract][Full Text] [Related]
20. Prostate stem cell antigen is a putative target for immunotherapy in pancreatic cancer.
Wente MN; Jain A; Kono E; Berberat PO; Giese T; Reber HA; Friess H; Büchler MW; Reiter RE; Hines OJ
Pancreas; 2005 Aug; 31(2):119-25. PubMed ID: 16024997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
